Scoreboard / REGN
Regeneron Pharmaceuticals, Inc. REGN
Week of October 8 to October 15, 2026 · Updated October 16, 2026
Setup Snapshot
The Setup in One Card
How REGN scored, how it moved against the market, and the catalyst behind the move. A high score means the stock deserves research time, not that it is a buy.
Friday Five Score
Weekly Rank
05 of 5
Sector Trend
Leadingup 5.4 percent
Actionability
Extended
Catalyst
Clinical Data84 week Phase 3 extension data showed zero new bone lesions against nine on placebo
Returns are measured from the Thursday, October 8 close to the Thursday, October 15 close. Benchmarks: S&P 500 -0.3% and Nasdaq Composite -1.8% for the week. Benchmark figures are official index closes; sector figures use SPDR sector ETF closes because the official S&P sector index closes for this window were not yet published at press time.
Why It Moved
The Story Behind the Move
Catalyst
On October 12, 2026 Regeneron released 84 week results from the Phase 3 OPTIMA extension of Pasatru in adults with fibrodysplasia ossificans progressiva: zero new heterotopic ossification lesions between weeks 56 and 84 against nine detected by scan on placebo, and one flare up at the higher dose against seventeen on placebo. The drug was approved in August 2026 and is the first approved treatment for the condition.
Why It Mattered
Zero is a rare word in clinical data and this is confirmation rather than hope, on a drug already approved. But the attribution is thin and published as thin: health care rose 5.37 percent as a sector and Regeneron beat its own sector by only 0.8 and 0.5 percentage points on the two days it moved, so roughly two of its 7.68 percent is company specific.
Risk Note
The most extended pick in the issue at 92.7 percent of its 52 week high after a 39.9 percent year, on confirmatory data in an ultra rare condition that cannot re rate a company this size by itself.
Reader Takeaway
Measure a move against its own sector before crediting the news. Most of this one was the health care bid, and saying so is more useful than claiming the data did all the work.
Continue the Research
Put REGN Back in Context
The stock page is one piece of the weekly research. Continue with the original issue, the full public ranking, or the method behind the analysis.
This page is for educational and informational purposes only. It is not financial advice, investment advice, or a recommendation to buy or sell any security.